Antiarrhythmics: Elimination and Dosage Considerations in Hepatic Impairment

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.46, Iss.12, 2007-01, pp. : 985-996

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiretroviral Therapy: Pharmacokinetic Considerations in Patients with Renal or Hepatic Impairment

By McCabe Sarah M. Qing Slish Judianne C. Catanzaro Linda M. Sheth Neha DiCenzo Robert Morse Gene D.

Clinical Pharmacokinetics, Vol. 47, Iss. 3, 2008-01 ,pp. : 153-172

Adis International

Access to resources Recommend Favorite

Adjust valganciclovir dosage in renal impairment

Inpharma, Vol. 1, Iss. 1359, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

The role of hepatic transporters in drug elimination

By Funk Christoph

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 4, 2008-04 ,pp. : 363-379

Informa Healthcare

Access to resources Recommend Favorite

Ximelagatran, melagatran dosage in severe renal impairment

Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Drug dosage in renal impairment: variation in recommendations

Inpharma, Vol. 1, Iss. 1490, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite